Mediocre Vaccine Could Make Pandemic Worse, Non-Profit Group Tells US FDA
Executive Summary
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.
You may also be interested in...
NIH Considering Trial of COVID-19 Vaccines and Asymptomatic Transmission
US FDA’s Peter Marks says transmission prevention is one of three key missing data points he’d like from Pfizer and BioNTech’s newly authorized vaccine. Another concern is how the vaccine will work is the virus “drifts.”
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.